Clinical trials: Advanced Solid Tumors (Phase 1)
Cancer, Neoplasms
Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma
The purpose of this study is to determine the maximum tolerated dose of Debio 0932 when administered orally, every-other-day or daily during the first 30 days, in patients with solid tumours or lymphoma.
- Conditions
- Cancer, Neoplasms, Solid Tumors, Lymphoma
- Trial name
- NCT01168752
- Testing
- Debio 0932
- Where
- 3 sites in France
- Volunteers
- 81 people
- Sponsor
- Debiopharm International SA
Neoplasms, Breast Neoplasms
Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
The main purpose of this study is to determine if AZD8931 can improve the efficacy of standard chemotherapy for the treatment of advanced breast cancer.
- Conditions
- Neoplasms, Breast Neoplasms, Breast Cancer
- Trial name
- THYME (NCT00900627)
- Testing
- AZD8931, Paclitaxel
- Where
- 38 sites in Belgium, Brazil and 12 more
- Volunteers
- 330 people
- Sponsor
- AstraZeneca
Cancer
A Study of TAVO412 in Patients with Cancer (TAVO412)
TAVO412 Phase 1 is an open-label, non-randomized, 2-part Phase I study to examine the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of TAVO412.
- Trial name
- NCT06761651
- Testing
- TAVO412
- Where
- 6 sites in China
- Volunteers
- 50 people
- Sponsor
- Tavotek Biotherapeutics
Advanced Solid Tumors With and Without Brain Metastases
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain metastases).
- Trial name
- NCT00539383
- Testing
- ANG1005
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Angiochem Inc
Solid Tumors, Neoplasms
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount
- Trial name
- NCT06431594
- Testing
- Mocertatug rezetecan
- Where
- 65 sites in United States, Argentina and 13 more
- Volunteers
- 675 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumor
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the…
- Trial name
- MYTHIC (NCT04855656)
- Testing
- Lunresertib, RP-3500, Zedoresertib
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 464 people
- Sponsor
- Debiopharm International SA
Solid Cancers, BRCA Mutation
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function…
- Conditions
- Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer
- Trial name
- NCT06614751
- Testing
- DAT-2645 tablet
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of Anvumetostat in combination with IDE397 in adult participants with…
- Trial name
- NCT05975073
- Testing
- Anvumetostat, IDE397
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 53 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Advanced Solid Tumors
A Study of HDM2024 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: Is the drug safe and tolerable ? Does the drug exhibit antitumor activity ?…
- Trial name
- NCT07539285
- Testing
- HDM2024
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Melanoma Stage IV, Solid Tumor
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy.
- Trial name
- NCT06425926
- Testing
- GIM-531, Anti-PD-1 monoclonal antibody
- Where
- 11 sites in United States
- Volunteers
- 117 people
- Sponsor
- Georgiamune Inc
Advanced Solid Tumours
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
This Phase I study is primarily designed to evaluate the safety and tolerability of AZD2811 at increasing doses in patients with advanced solid tumours and for whom no standard of care exists.
- Trial name
- NCT02579226
- Testing
- AZD2811
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Neoplams
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors
A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors. The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity…
- Trial name
- NCT07644650
- Testing
- MST-168
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
Advanced Solid Tumors
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
- Trial name
- NCT06730750
- Testing
- BMS-986490, Bevacizumab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 360 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer, Non-small Cell Lung Cancer
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
This amended expansion phase of the protocol is to further the experience at a dose level of 150 mg CPT eq/m2 in patients with Stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and to test for…
- Trial name
- NCT00455052
- Testing
- XMT-1001
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mersana Therapeutics
Advanced or Metastatic Solid Tumors
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors.
- Trial name
- NCT06389526
- Testing
- CHS-1000, Toripalimab
- Volunteers
- 48 people
- Sponsor
- Coherus Oncology, Inc.
Locally Advanced (Unresectable) or Metastatic Solid Tumors
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).
- Trial name
- NCT07612176
- Testing
- NEOK001, NEOK001 RDE
- Where
- 9 sites in United States
- Volunteers
- 155 people
- Sponsor
- NEOK Bio, Inc.
Advanced Solid Tumors
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
The study will evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-1088 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors who have not responded to conventional…
- Trial name
- NCT05394350
- Testing
- MK-1088, Pembrolizumab
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
The purpose of this trial is to learn about the safety and effectiveness of the antibody GEN1079 in participants with certain types of cancer. The trial has multiple parts.
- Trial name
- NCT07387068
- Testing
- GEN1079
- Where
- 12 sites in United States, Spain
- Volunteers
- 121 people
- Sponsor
- Genmab
Solid Tumor
A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors
This study is a non-randomized, open, multiple administration and dose escalation phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetic/pharmacodynamics Characteristics of multiple oral administration of…
- Trial name
- NCT03844438
- Testing
- LPM3480226
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Luye Pharma Group Ltd.